Vitality Biopharma Receives DEA Approval for Cannabinoid Pharma Development Facility

Approval of cannaboside pharmaceutical research included review by FDA and California Research Advisory Panel LOS ANGELES, CA VBIO, (Marketwired Dec 21, 2016) Vitality Biopharma, Inc. (OTCQB: VBIO) ( Vitality Biopharma, Vitality, or the Company ), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it has received approval from both the U.S. Drug Enforcement Agency (DEA) and the State of
http://bit.ly/2h2bO13